Please login to the form below

Not currently logged in
Email:
Password:

Diabetes drug gets good review

The Committee for Medicinal Products for Human use (CHMP) has recommended that a new medicine to treat Type II diabetes be approved for use in Europe.

The Committee for Medicinal Products for Human use (CHMP) has recommended that a new medicine to treat Type II diabetes be approved for use in Europe.

Sitagliptin/metformin has been developed to provide a significant reduction in glucose levels in patients with diabetes. The drug was licensed for use in the UK in 2007 and is manufactured under the brand name Janumet by Merck Sharp & Dhome. The company could potentially be in a position to supply its branded medicine to 27 countries in the European market, including Norway and Iceland, should regulatory authorities adopt CHMP's recommendation.

Kamlesh Khunti, professor of primary care diabetes and vascular medicine at the University of Leicester, said: "Many patients remain poorly controlled on their existing oral combination therapy. In order to improve quality of life for our patients, we need simple and effective treatments that address glucose control and common tolerability issues such as hypoglycaemia and weight gain."

A 30-week placebo-controlled clinical study showed that sitagliptin/metformin had a high level of efficacy when reducing blood sugar levels. A decision regarding marketing authorisation by the European Medicines Agency (EMEA) is expected in mid June 2008.

25th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics